Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03748446 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial completedFinal enrollment: 13 participants (planned 20) · Primary completion date changed from estimate of Sep 1, 2026 to Nov 6, 2025 · Eligibility criteria expanded, about 20 words · 1 moreShow 4 more changesShow less
Final enrollment: 13 participants (planned 20)
Primary completion date changed from estimate of Sep 1, 2026 to Nov 6, 2025
Eligibility criteria expanded, about 20 words
Publications: details revised at 9 of 9 entries
MinorTrial status: Recruiting to Active, Not RecruitingSite details revisedv6Show 1 more changeShow less
Site details revised
NotablePrimary completion date: Sep 1, 2024 to Sep 1, 2026Completion date: Dec 1, 2024 to Dec 1, 2026v5Show 1 more changeShow less
Completion date: Dec 1, 2024 to Dec 1, 2026
NotablePrimary completion date: Dec 1, 2023 to Sep 1, 2024v4
NotablePrimary completion date: Dec 1, 2022 to Dec 1, 2023v3
NotableTrial status: Not Yet Recruiting to RecruitingPrimary completion date: Dec 15, 2021 to Dec 1, 2022 · Start date changed from estimate of Dec 15, 2018 to Dec 5, 2019 · Study sites: 0 to 1 · 1 morev2Show 4 more changesShow less
Primary completion date: Dec 15, 2021 to Dec 1, 2022
Start date changed from estimate of Dec 15, 2018 to Dec 5, 2019
Study sites: 0 to 1
Completion date: Dec 15, 2021 to Dec 1, 2024
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.